Restore Mind Medicine

The Disparity Between MindMed and the FDA "Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose" - MindMed Press Release May 19, 2022 "The [FDA] ... requested Additional Preclinical Characterization of MM-110 that will now be required prior to initiating the proposed Phase 2a trial in the US. We agree with the [FDA] ." - MindMed Earnings Call August 11, 2022 39

View entire presentation